STANDARD BIOTOOLS INC. — Director's Dealing 2023

May 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2023-05-17

Reporting Person: Casdin Partners Master Fund, L.P. (Director, 10% Owner)
Reporting Person: Casdin Capital, LLC (Director, 10% Owner)
Reporting Person: Casdin Partners GP, LLC (Director, 10% Owner)
Reporting Person: Casdin Private Growth Equity Fund II, L.P. (Director)
Reporting Person: Casdin Private Growth Equity Fund II GP, LLC (Director)
Reporting Person: Casdin Partners FO1-MSV, LP (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-17	Common Stock	P	250000	$1.8862	Acquired	250000	Indirect
2023-05-18	Common Stock	P	150000	$2.1591	Acquired	400000	Indirect
2023-05-19	Common Stock	P	800000	$2.2949	Acquired	1200000	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.